Pam2Cys
Based on 1 Customer Validation
Pam2Cys (Dipalmitoyl-S-glyceryl-cysteine; S-[2,3-Bis(palmitoyloxy)propyl]cysteine) is a TLR2 agonist and immunostimulant. Pam2Cys binds to TLR2 to activate dendritic cells and trigger the TLR2-dependent NF-κB signaling pathway. Pam2Cys also induces dendritic cell maturation by upregulating the expression of cell surface MHC II molecules. Pam2Cys activates innate immune signaling pathways, drives pro-inflammatory and antimicrobial responses, enhances the expression of macrophage activation markers, increases phagocytic activity, induces the release of IL-12 and pro-inflammatory cytokines, and polarizes macrophages into a pro-inflammatory, antimicrobial phenotype without interfering with IL-10-induced macrophage polarization. Pam2Cys also serves as the lipid moiety in synthetic lipopeptide vaccines and possesses self-adjuvant properties. Pam2Cys enhances the immunogenicity of conjugated peptide segments and induces cellular and humoral immune responses. However, it does not activate CD4 T cells in mouse splenocyte cultures when used alone. Pam2Cys activates pulmonary TLR2 signaling pathways, triggers innate immune responses, recruits neutrophils and macrophages, induces the secretion of various cytokines, alleviates symptoms and damages associated with influenza A virus infection in mice without impairing adaptive immunity. Pam2Cys can be used in studies related to tuberculosis and influenza A virus infection.
For research use only. We do not sell to patients.
- Purity: 99.82%
- CAS No.: 656831-18-4
- Formula: C38H73NO6S
- Molecular Weight:672.05
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
NF-κB Signaling Compound Library
HY-L014
-
Stem Cell Signaling Compound Library
HY-L017
-
Antiviral Compound Library
HY-L027
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Pyroptosis Compound Library
HY-L059
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Transcription Factor-Targeted Library
HY-L090
-
Pain-Related Compound Library
HY-L139
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Autoimmune Disease Compound Library
HY-L156
-
Immunopotentiator Compound Library
HY-L172
-
Macrophage Related Compound Library
HY-L174
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Pattern Recognition Receptors Library
HY-L237
-
Lactylation Compound Library
HY-L249
Biological Activity
|
TLR2 |
The Pam2Cys-containing lipopeptide construct (0.025-0.25 nmol/mL; 5 h) potently activates NF-κB signaling through TLR2 in HEK293 cells[1].
Pam2Cys (10-100 ng/mL; 24 h) increases the phagocytic activity of porcine monocyte-derived macrophages, with a stronger effect at the higher dose[2].
Pam2Cys (10-100 ng/mL; 4 h, 8 h, 24 h) upregulates the gene expression of IL-1β, IL-6, TNF-α, and IL-12p40 at 4, 8, and 24 h, and IL-10 at 4 and 8 h, in porcine monocyte-derived macrophages[2].
Pam2Cys (10-100 ng/mL; 4 h, 8 h, 24 h) upregulates the gene expression of multiple IFN-α subtypes (IFN-α1, IFN-α2, IFN-α5/6, IFN-α9 at 8 h; IFN-α16 at 24 h), downregulates IFN-α3 at 24 h, and does not alter IFN-β expression, in porcine monocyte-derived macrophages[2].
Pam2Cys (10-100 ng/mL; 4 h, 8 h, 24 h) downregulates the gene expression of TLR3, TLR4, TLR5, TLR7, TLR8, and TLR9 in porcine monocyte-derived macrophages at multiple time points (4, 8, 24 h) post-treatment[2].
Pam2Cys (50-100 ng/mL; 72 h) alone does not activate CD4 T cells from L91-immunized mice[3].
Pam2Cys (10 nmol; 24 h) induced primary mouse lung cells to exhibit significantly elevated levels of IL-6, IL-10, MCP-1, IFN-γ, and TNF-α, with no change in IFN-α levels[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:porcine monocyte-derived macrophages
-
Concentration:10-100 ng/mL
-
Incubation Time:4 h, 8 h, 24 h
-
Result:Upregulated the gene expression of multiple IFN-α subtypes (IFN-α1, IFN-α2, IFN-α5/6, IFN-α9 at 8 h; IFN-α16 at 24 h), downregulates IFN-α3 at 24 h, and does not alter IFN-β expression.
Upregulated the gene expression of IL-1β, IL-6, TNF-α, and IL-12p40 at 4, 8, and 24 h, and IL-10 at 4 and 8 h.
Downregulated the gene expression of TLR3, TLR4, TLR5, TLR7, TLR8, and TLR9 in porcine monocyte-derived macrophages at multiple time points (4, 8, 24 h) post-treatment
Immunization with the Pam2Cys-conjugated construct L91 (20-10 nmol per animal; i.p. or s.c., i.p.) induces Th1-skewed dendritic cell activation, robust and enduring CD4 T-cell memory responses, and significantly better protection against Mycobacterium tuberculosis aerosol challenge in mice than BCG, with a 40% reduction in lung bacterial burden relative to BCG[3].
Pam2Cys (20 nmol; i.n.; single dose) provides dose-dependent viral load reduction of up to 88% in mice challenged with mild IAV, with efficacy persisting for at least 7 days post-administration[4].
Pam2Cys (20 nmol; i.n.; single dose) prophylaxis preserves the development of functional, memory-phenotype IAV-specific CD8+ T cells in mice, with enhanced responses in the spleen and reduced but detectable responses in the lungs[4].
Pam2Cys (20 nmol; i.n.; single dose) reduces IAV viral load by over 99% in the trachea and lungs of BALB/c mice, with no effect on nasal turbinate infection[4].
Pam2Cys (20 nmol; i.n.; single dose) provides TLR2-dependent, type 1 interferon-independent protection against virulent IAV in mice, with 92% survival and significant weight loss reduction[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice with Influenza A virus infection (male and female, 6-12 weeks old)[4]
-
Dosage:20 nmol
-
Administration:i.n.; single dose
-
Result:Reduced viral titers by 99.4% in the trachea and 99.91% in the lungs relative to saline-treated controls; no reduction was observed in nasal turbinates.
Virus was undetectable in 7 of 11 treated mice’s lungs.\nReduced viral loads by 10-100-fold across nasal turbinates, trachea, and lungs in donor mice relative to saline-treated donors.
Completely prevented transmission to naive recipients when donors were treated 24 or 72 hours prior to challenge; reduced but did not eliminate transmission when donors were treated 5 or 7 days prior to challenge.
-
Animal Model:C57BL/6 mice with Innate immune activation (male and female, 6-12 weeks old); TLR2-deficient (TLR2−/−) on C57BL/6 background (male and female, 6-12 weeks old); BALB/c (male and female, 6-12 weeks old)[4]
-
Dosage:20 nmol
-
Administration:i.n.; single dose
-
Result:Elevated BAL fluid levels of IL-6, IL-10, MCP-1, IFN-γ, and TNF-α significantly, and increased lung populations of neutrophils, interstitial macrophages, alveolar macrophages, lymphocytes, γδ T cells, and activated IFN-γ-producing NK cells significantly in C57BL/6 and BALB/c mice at 72 hours post-administration.
Returned cytokine levels and most innate cell populations to baseline by day 7, but lymphocyte counts remained elevated.
Observed no cytokine or cell population changes in TLR2−/− mice.
Chemical Information
-
CAS No. 656831-18-4
-
Appearance Solid
-
Molecular Weight 672.05
-
Formula C38H73NO6S
-
Color White to off-white
-
SMILES
O=C([C@@H](N)CSCC(OC(CCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCC)=O)O
-
Synonyms
Dipalmitoyl-S-glyceryl-cysteine; S-[2,3-Bis(palmitoyloxy)propyl]cysteine
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMF : 3.33 mg/mL (4.95 mM; ultrasonic and warming and adjust pH to 4 with 1 M HCl and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zeng W, et al. Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys. Amino Acids. 2010;39(2):471-480. [Content Brief]
[2]. Franzoni G, et al. Targeting Toll-Like Receptor 2: Polarization of Porcine Macrophages by a Mycoplasma-Derived Pam2cys Lipopeptide. Vaccines (Basel). 2021;9(7):692. Published 2021 Jun 23. [Content Brief]
[3]. Gowthaman U, et al. Promiscuous peptide of 16 kDa antigen linked to Pam2Cys protects against Mycobacterium tuberculosis by evoking enduring memory T-cell response. J Infect Dis. 2011;204(9):1328-1338. [Content Brief]
[4]. Tan AC, et al. Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice. Mol Pharm. 2012;9(9):2710-2718. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMF | 1 mM | 1.4880 mL | 7.4399 mL | 14.8798 mL | 37.1996 mL |
Pam2Cys Related Classifications
Cat. No.: HY-165613
Powered by Bioz
- Pam2Cys
- 656831-18-4
- Dipalmitoyl-S-glyceryl-cysteine
- S-[2,3-Bis(palmitoyloxy)propyl]cysteine
- Toll-like Receptor (TLR)
- Influenza Virus
- NF-κB
- HEK293 cells
- CD4 T cells
- MHC Class II
- monocyte-derived macrophages
- Mycobacterium tuberculosis
- neutrophils
- influenza A virus
- NF-κB signaling
- dendritic cells
- TLR2
- Inhibitor
- inhibitor
- inhibit